MannKind Corp Market Cap ($1.13 Billion)
Market Cap & Net Worth: MannKind Corp (MNKD)
MannKind Corp market cap. MannKind Corp (NASDAQ:MNKD) has a market capitalization of $1.13 Billion ($1.13 Billion) as of October 31, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8152 globally and #2425 in its home market, demonstrating a 14.75% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying MannKind Corp's stock price $3.50 by its total outstanding shares 321544484 (321.54 Million).
MannKind Corp Market Cap History (2015–2026)
MannKind Corp market cap history from 2015 to 2026. Data shows change from $2.33 Billion to $1.13 Billion (-13.27% CAGR). Check MNKD stock price for real-time trading data and today's change.
Index Memberships
MannKind Corp is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Dow Jones Biotechnology
DJUSBT
|
$1.15 Trillion | 0.10% | #23 of 39 |
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.04% | #238 of 976 |
|
NASDAQ Composite
IXIC
|
$40.85 Trillion | 0.00% | #897 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.06% | #137 of 263 |
Weight: MannKind Corp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
MannKind Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how MannKind Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see cash efficiency ratio of MannKind Corp for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
5.22x
MannKind Corp's market cap is 5.22 times its annual revenue
Latest Price to Earnings (P/E) Ratio
310.96x
MannKind Corp's market cap is 310.96 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.02 Billion | $174.76 Million | $125.66 Million | 5.86x | 8.15x |
| 2017 | $745.98 Million | $11.74 Million | -$117.33 Million | 63.51x | N/A |
| 2018 | $340.84 Million | $27.86 Million | -$86.97 Million | 12.23x | N/A |
| 2019 | $414.79 Million | $63.04 Million | -$51.90 Million | 6.58x | N/A |
| 2020 | $1.01 Billion | $65.14 Million | -$57.24 Million | 15.45x | N/A |
| 2021 | $1.41 Billion | $75.44 Million | -$80.93 Million | 18.63x | N/A |
| 2022 | $1.69 Billion | $99.77 Million | -$87.40 Million | 16.98x | N/A |
| 2023 | $1.17 Billion | $198.96 Million | -$11.94 Million | 5.88x | N/A |
| 2024 | $2.07 Billion | $285.50 Million | $27.59 Million | 7.24x | 74.94x |
| 2025 | $1.82 Billion | $348.97 Million | $5.86 Million | 5.22x | 310.96x |
Competitor Companies of MNKD by Market Capitalization
Companies near MannKind Corp in the global market cap rankings as of October 31, 2026. See how leveraged is MannKind Corp's balance sheet to understand what proportion of total assets are financed by equity.
Key companies related to MannKind Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #183 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #374 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #422 globally with a market cap of $67.80 Billion USD ( AU$95.82 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #498 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #183 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $540.00 |
| #374 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $818.77 |
| #422 | CSL Ltd | AU:CSL | $67.80 Billion | AU$197.50 |
| #498 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $222.76 |
Market Capitalization of MannKind Corp (2015–2026)
Market capitalization of MannKind Corp from 2015 to today. Between 2015 and today, MannKind Corp's market cap moved from $2.33 Billion to $ 1.13 Billion, with a yearly change of -13.27%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.13 Billion | -38.27% |
| 2025 | $1.82 Billion | -11.82% |
| 2024 | $2.07 Billion | +76.65% |
| 2023 | $1.17 Billion | -30.93% |
| 2022 | $1.69 Billion | +20.59% |
| 2021 | $1.41 Billion | +39.62% |
| 2020 | $1.01 Billion | +142.64% |
| 2019 | $414.79 Million | +21.70% |
| 2018 | $340.84 Million | -54.31% |
| 2017 | $745.98 Million | -27.12% |
| 2016 | $1.02 Billion | -56.09% |
| 2015 | $2.33 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of MannKind Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.13 Billion USD |
| MoneyControl | $1.13 Billion USD |
| MarketWatch | $1.13 Billion USD |
| marketcap.company | $1.13 Billion USD |
| Reuters | $1.13 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About MannKind Corp
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve… Read more